2022.05.18.

Seasun Biomaterials (CEO Park Hee-kyung), a company specializing in genomic diagnosis, announced on the 16th that it had signed a business agreement with Seoul National University Medical School for the development and establishment of an epigenetic genome-based precision medical system.

The company has recently completed the development of a high-risk Lynch Syndrome screening test, which was promoted by the Ministry of Trade, Industry and Energy’s ‘Post Genome Multi-Business Genome Project’. Based on this, an agreement with Seoul National University was promoted to develop early diagnosis and customized treatment for cancer patients. Ultimately, the goal is to commercialize a lifelong personalized health management system.

Seasun Bio's strategy is to spread the 'Lynch syndrome cancer disease high-risk screening system' for screening tests or self-diagnosis for the general public, while leading the preemptive prevention and treatment of cancer through detailed tests for people classified as high-risk groups.

Park Hee-kyung, CEO of Seasun Bio, said, “Epigenetic genomic mutations caused by the living environment and aging mechanisms provide clues to the development of diseases that cannot be explained only by congenital genetic abnormalities and family history. It will be a valuable opportunity to contribute to the development of molecular diagnostics and precision medicine.”

Kim Jong-un, dean of Seoul National University School of Medicine (professor of neurosurgery) said, “Through today’s event, the two institutions are to establish a cooperative system and promote mutual development. We look forward to continuing exchanges and cooperation between the two organizations in the future.”

Lynch syndrome is an autosomal-dominantly inherited disease, with an up to 82% chance of developing cancer. In particular, the probability of developing secondary cancer within 15 years of initial cancer diagnosis is 50% or more, which is 25 times higher than that of normal people.